Skip to main content
. 2018 May 25;9(40):25891–25902. doi: 10.18632/oncotarget.25401

Figure 5. Fap1-inhibition decreases abundance of CD133+CD44+ cells in in a murine xenograft model of colon cancer with or without oxaliplatin.

Figure 5

Tumors from the mice described above were analyzed for cell population distribution after various treatments. (A) Histograms from flow cytometry demonstrate decreased abundance of CD133+CD44+ cells after treatment with SLV peptide with or without oxaliplatin. A representative histograms for each cohort is shown. (B) Treatment with SLV peptide decreases relative abundance of CD133+CD44+ cells in xenograft tumors. Tumors were simultaneously harvested from mice treated with SLV peptide versus VLS control (when control group tumors were >2,000 mm3) and analyzed for CD133 and CD44 expression by flow cytometry. Significant differences indicated by *, **, or ***. (p<0.001, n=6). (C) The addition of SLV peptide to oxaliplatin treatment decreases relative abundance of CD133+CD44+ cells in xenograft tumors. Tumors were simultaneously harvested from mice treated with oxaliplatin + SLV peptide versus VLS control (when control group tumors were >2,000 mm3) and analyzed for CD133 and CD44 expression by flow cytometry. Significant differences indicated by *, **, or ***. (p<0.001, n=6).